SecBot SecBot
8-K ·Filed Jun 24, 2026

PASG

Passage BIO, Inc.
BEARISH
Impact 7/10
Horizonmonths Processed4mo ago SEC0001104659-26-077306
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

The merger effectively ends Passage Bio as an independent entity. Current shareholders face massive dilution with only 7% pro forma ownership. The CVRs offer a speculative tailwind from legacy asset monetization but are highly uncertain. Monitor the shareholder vote and Nasdaq listing approval; if the deal closes, PASG will trade as a Remix Therapeutics entity with a new pipeline focus on REM-422.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.33
T+0 close · Jun 24, 2026 · via day close
Latest settled
+9.70%
T+60 · $4.75
Vs SPY
+5.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 25 $4.33entry
  2. T+1 · 5mo ago +8.54%α +9.27% · $4.70
  3. T+5 · 5mo ago +5.77%α +4.21% · $4.58
  4. T+20 · 4mo ago +13.16%α +12.64% · $4.90
  5. T+60 · 8w ago +9.70%α +5.97% · $4.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Passage Bio entered into a definitive all-stock merger agreement with Remix Therapeutics, where pre-merger Passage shareholders will own only ~7% of the combined company. The deal is supported by an oversubscribed $100M+ PIPE led by Decheng Capital, funding the combined entity into 2028 to advance Remix's lead oral MYB mRNA degrader REM-422. Passage shareholders also receive contingent value rights tied to legacy gene therapy milestones, but the massive dilution and effective change of control make this a highly negative event for current PASG holders.

Key Financial Metrics

Deal Type
merger
Offering Size
$99.9M

Key Facts

  • Passage Bio shareholders will own approximately 7% of the combined company post-merger, with Remix shareholders (including PIPE investors) owning ~93%
  • Concurrent PIPE of $69,999,999.28 plus convertible notes totaling at least $99,929,000 in gross proceeds
  • Remix Equity Value set at $226M, Passage Equity Value at $20M in the merger exchange ratio
  • Passage will change its name to Remix Therapeutics, Inc. and board/management will be replaced by Remix designees
  • Contingent Value Rights (CVRs) issued to Passage shareholders for potential payments from legacy asset monetization (GM1 and MLD programs) through 2028
  • Passage's existing gene therapy programs (PBFT02) are being wound down or divested as Legacy Assets

Financial Impact

Pre-merger Passage shareholders diluted to ~7% ownership of combined entity; combined company receives $100M+ in new capital; CVRs provide speculative upside from legacy asset payments (80% of GM1 payments and 100% of MLD payments, less deductions)

dilutionownership_percentagecash_positionenterprise_value

Risk Factors

  • Deal may fail to close if Passage shareholders vote against the issuance or charter amendment
  • CVR payments may be zero if Gemma does not make milestone payments or if Permitted Deductions consume proceeds
  • Combined company's success depends entirely on Remix's unapproved drug REM-422, which carries clinical and regulatory risk
  • Potential stockholder litigation challenging the merger terms

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
64% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-077306
Document: tm2618476d1_ex10-6.htm0001104659-26-077306
Document: tm2618476d1_ex10-4.htm0001104659-26-077306

Track record

15 reports on PASG

Performance horizon

2 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
  2. Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
  3. Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
  4. Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
  5. Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
  6. Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
  8. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  9. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  10. Jun 24, 202620w ago 8-K Bearish 7/10 Viewing Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 24, 2026